The therapeutic vaccine, codenamed mRNA-4359, is intended to boost people's immunity to a variety of advanced solid tumor ...

The company reported Health Canada authorized the use of its Spikevax KP.2 shot for those aged six months and older. Last ...

Moderna's mRNA-4359 has shown early signs of efficacy, activating key proteins to trigger an immune response for cancer ...

Moderna (MRNA) plans to launch a skin cancer vaccine developed with Merck (MRK) in 2025, but faces stock pressure after ...

Health Canada authorized Moderna's updated COVID-19 vaccine on Tuesday to roll out in fall and winter immunization campaigns.

Moderna shares are moving higher on Tuesday after the company announced that Health Canada approved its updated COVID-19 ...

SPIKEVAX® is the first updated COVID-19 vaccine authorized in Canada for 2024-2025, offering a timely solution to help protect Canadians ...

Moderna has delayed its break-even goal by two years, pushing it to 2028, due to slower regulatory processes for key products ...

Covid-19 levels in the United States are high and rising, flu season is approaching quickly and RSV cases are already ...

These extra doses will bring more highly specialised work making these novel molecules to contract manufacturing ...

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, ...